title: Experimental combination chemotherapy of pirarubicin with various antitumor drugs against P388 murine leukemia.
abstract: We have examined the therapeutic effects of combination therapy of pirarubicin ((2"R)-4'-O-tetrahydropyranyladriamycin, THP) with various antitumor agents against P388 murine leukemia. THP showed a high antitumor activity in combination with various antitumor drugs, especially with cyclophosphamide (CPM), cisplatin (CDDP), mitomycin C (MMC), enocitabine (BHAC), vindesine (VDS) or methotrexate (MTX). The effects of combination therapy depended on the order of administration of THP and combined drugs. THP-preceding treatment gave more synergistic effects in combination with 5-fluorouracil (5-FU) or MTX. THP-preceding or simultaneous treatment with etoposide (ETP) indicated the higher synergistic activity than ETP-preceding one. Moreover, THP showed much higher synergistic effects in any order of the combination with CPM, CDDP, MMC, BHAC, VDS or MTX. These results suggest that THP possesses a therapeutic usefulness clinically in combination with various antitumor drugs, if the selection of drugs combined with THP and the order of administration are suitable.
authors.affiliation: Central Research Laboratories, Mercian Corp, Fujisawa, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Izumi
authors.forename: S
authors.initials: S
authors.lastname: Hirano
authors.forename: Y
authors.initials: Y
authors.lastname: Matsushita
authors.forename: H
authors.initials: H
authors.lastname: Iguchi
authors.forename: H
authors.initials: H
authors.lastname: Tone
authors.forename: T
authors.initials: T
authors.lastname: Takeuchi
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004354:Drug Screening Assays, Antitumor; D005472:Fluorouracil / Q000008:administration & dosage; D007941:Leukemia P388 / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D051379:Mice; D008807:Mice, Inbred BALB C; D016685:Mitomycin / Q000008:administration & dosage; D017663:Peplomycin / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D016685:Mitomycin; D017663:Peplomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; C015019:enocitabine; C027260:pirarubicin; D015122:Mercaptopurine; D002945:Cisplatin; D014751:Vindesine; D005472:Fluorouracil; D008727:Methotrexate